How device interviews use role plays
Device hiring processes are long on purpose. It is common to go through five, six, or more stages — recruiter screen, hiring manager, a field ride-along, a panel, sometimes a personality or talent assessment scored on drive and resilience in general terms, and a final presentation or role play. The role play usually lands near the end, once they already believe you can do the numbers and want to see how you carry yourself in front of a clinician.
The scenario mirrors the job: a short profile of a surgeon, a few facts about your device and its evidence, and a tight window — often ten minutes between cases. You play the rep; the interviewer plays the surgeon, efficient, skeptical, and protective of OR time. Some companies run a pure presentation format to a panel instead, but the conversion role play reveals the most.
Unlike a pharma call, the device role play is as much about workflow and reliability as clinical data. A surgeon isn't just deciding whether your evidence is credible — he's deciding whether letting you into his operating room is worth the risk to his outcomes and his block time.
What's different from pharma
OR access, not office access. In pharma the barrier is the front-desk gatekeeper. In device it's the sterile field — you earn a credible place in the operating room and get trusted to support a live case. Access is about clinical credibility, not persistence.
Surgeon conversion, not prescriber habit. You're not asking for one patient's script. You're asking a surgeon to change an implant system he knows cold, whose trays his team turns over fast. Switching threatens his outcomes and efficiency at once, so the ask must be small: one evaluation case, not a conversion.
Evidence selling with honest limitations. Registry outcomes and revision-rate data carry the argument. But newer devices have shorter follow-up horizons, and a surgeon catches overclaiming instantly. Conceding the limitation earns the credibility to ask for the case.
Economic and VAC buyers are real. Unlike pharma, device selling openly involves cost-per-case, value analysis committee (VAC) review, consignment, and budget. You can and should talk economics — tray consolidation, OR-time savings, revision reduction — as part of the case.
Case support is the product. Surgeons have been burned by reps who promised outcomes at launch and vanished. Your reliability — covering cases personally, training the OR team, being reachable — is half of what you're selling.
A full worked example: the competitor-loyal surgeon
You have ten minutes with Dr. Marcus Reyes, a high-volume orthopedic surgeon who does about 350 total knees a year on the Meridian competitor system — call it the Apex knee — and has for ten years. His revision rate is low and he's proud of it. You represent the fictional Vanta Knee System from Northstar Orthopedics. Your evidence: a registry showing a lower five-year cumulative revision rate driven by less aseptic loosening, an instrument set that consolidates to two trays versus the incumbent's four, and one real limitation — Vanta is newer, so long-horizon follow-up is shorter. Watch the concession-and-ask structure.
Dr. Reyes
I've got ten minutes between cases. I've been doing Apex knees for a decade — what could you possibly show me?
Rep
Fair question, and I'm not going to pretend Apex is broken — your revision rate is exactly why I respect the system you run. Before I show you anything, can I ask: what's driving the revisions you do see, and how fast is your team turning over the case today?
Dr. Reyes
Revisions are rare. When they happen it's loosening, years out. And my team is fast — four trays, but they know them cold. Setup isn't my bottleneck.
Rep
That's the exact issue the Vanta registry speaks to. At five years it shows a lower cumulative revision rate than the category benchmark, and the difference is driven mostly by less aseptic loosening — the failure mode you just named. I'm not asking you to change your practice on that. I'm asking whether one case is worth seeing if it holds up in your hands.
Dr. Reyes
My revision rate is already low. Why would I change what works?
Rep
You shouldn't change what works — that's not the ask. The ask is one evaluation case on a defined patient type, fully covered by me, so the evidence you weigh most is your own, not my slides. If it doesn't hold up, you've lost one case and learned something.
Dr. Reyes
My team is fast with the current trays. A new system slows my OR down, and my OR time is not free.
Rep
OR time is the whole game, I get it. Vanta runs on two trays instead of the four your Apex case sets up, with fewer instrument steps, so once your team's trained the turnover actually gets faster. I won't pretend the first case or two has no learning curve — that's exactly why I cover every evaluation case personally and bring clinical education in to train your team before we start.
Dr. Reyes
The last rep who promised me better outcomes disappeared right after launch. Why is this any different?
Rep
That's a fair thing to hold against my whole industry, and I won't talk you out of it with a promise. Here's the concrete commitment: I personally cover every evaluation case start to finish, you get my cell for direct access, and clinical education trains your team before the first case and stays through adoption. If I'm not in your OR when I said I'd be, the evaluation's off — you hold me to that.
Dr. Reyes
Registry data takes years to mean anything, and your device is too new to have it. So why should I trust the numbers?
Rep
You're right, and I'd lose your trust if I pretended otherwise — Vanta has shorter long-horizon follow-up than a legacy system, full stop. What the registry does show is a lower five-year cumulative revision rate than the benchmark, driven by less loosening, in a real population. I'm not asking you to bet your practice on it. I'm asking for one case.
Dr. Reyes
And the cost side? My materials manager will ask what this does to cost-per-case.
Rep
Happy to take that head-on with your VAC. The tray consolidation and fewer instrument steps cut processing and turnover cost, and if the revision reduction holds, the downstream reoperation savings are the real economic story. I can build that case with your value analysis committee whenever you want — but it starts with one case that gives you your own data to stand on.
Dr. Reyes
One case. Defined patient type. You're there start to finish.
Rep
That's the ask. Pick the next appropriate primary knee that fits the profile, I'll have clinical education train your team beforehand, and I'll be at the sterile field for the whole case. Can we get one on your schedule in the next two weeks?
Dr. Reyes
Talk to my scheduler on your way out. One case. We'll see.
Coaching note: The structure is concession, then ask. Every objection gets acknowledged before it gets answered, the newer-device limitation gets conceded honestly instead of spun, and the economics get addressed as a VAC conversation rather than dodged. And the close is a single evaluation case with a named patient type, full personal coverage, and a two-week window — the smallest yes a competitor-loyal surgeon can give, which is exactly why he gives it.
How the role play is scored
| What they score | What a pass looks like |
|---|---|
| Discovery and credibility | You establish credibility and learn his outcomes and OR workflow before positioning — asking about his revisions and turnover before you pitch. |
| Clinical evidence selling | You use the registry revision-rate data accurately, tie it to his failure mode (loosening), and concede the shorter follow-up horizon. |
| Converting surgeon preference | You validate his outcomes rather than attacking the incumbent, and frame a low-risk single evaluation case instead of a switch. |
| Objection handling | You acknowledge each concern — outcomes, OR time, the disappearing rep, data maturity — before responding with the accurate answer for it. |
| Economic and VAC navigation | You pair the clinical case with a credible economic one — tray consolidation, turnover, revision savings — and offer to build the VAC case. |
| Closing and gaining agreement | You explicitly ask for one evaluation case with full personal coverage and secure a concrete next step, not 'send me the data.' |
Run this surgeon conversion against an AI
Practice the competitor-loyal surgeon call with the ten-minute window, and get scored on evidence selling, objection handling, and whether you earned the evaluation case.
Practice this scenarioCommon failure modes
Attacking the incumbent. Telling a surgeon his ten-year system is inferior insults his judgment and outcomes. Validate what works, then compete on the specific gap where your evidence is genuinely stronger.
Overclaiming past the data. Stretching a registry signal into a guarantee, or hiding the shorter follow-up horizon. He'll catch it and stop trusting everything else you said. Conceding the limitation buys credibility.
Asking for a switch instead of a case. Going for full conversion in one ten-minute call. It's too big a risk to accept, so he defaults to no. One evaluation case is the yes he can actually give.
Ignoring OR time and workflow. Selling only the implant and skipping the tray count, learning curve, and case coverage. To a surgeon, workflow disruption is a clinical risk, not a footnote.
Waving off the economics. Saying 'the rep team handles cost' when he raises VAC or cost-per-case. Device reps hold the economic conversation credibly — tie the budget case to the clinical one.
Closing on logistics. Ending with 'I'll send the registry paper' or 'let's stay in touch.' That's not a commitment. Name the case, the patient type, the coverage, and a date.
30-60-90 and brag-book expectations
Most device interviews also ask for a 30-60-90 day plan, scored for whether you understand what the job actually is. A weak plan is generic sales-speak; a strong one is specific to OR-facing device work. The first 30 days: vendor credentialing, product and surgical-technique certification, cadaver or sawbones lab time, and shadowing case coverage. Days 30-60: your first evaluations and account plans built by surgeon potential. Days 60-90: converting evaluations to adopted case types and starting VAC conversations for accounts worth contracting.
The brag book matters here too. Bring the ranking reports, quota attainment, President's Club, and launch results that prove your numbers, and be ready to walk a specific win. Interviewers pair the brag book with behavioral questions, so the conversion story in your binder should match the conversion instinct you show in the role play.
The behavioral round runs on STAR. Expect 'Tell me about a time you converted a surgeon who was loyal to a competitor's product,' 'Describe a time you supported a difficult case in the OR,' and 'Tell me about a time you won approval from a value analysis committee.' Answer each with a real Situation, Task, Action, and Result — and quantify it.
Rehearse the behavioral round
Practice the STAR behavioral questions a device panel actually asks — surgeon conversion, OR case support, VAC approval — scored for Situation, Task, Action, and Result.
Practice the behavioral interviewYour week-before prep plan
- 1
Days 7-6: learn the evidence and its limits
Master the headline outcome data you're given, what it does and does not show, and the honest limitation. Being able to concede the limitation cleanly is as important as citing the strength.
- 2
Days 5-4: build the workflow and economic story
Know the tray count, the instrument-step difference, the learning curve, and the cost-per-case and VAC angle. Practice saying the economic case in two sentences that tie back to clinical value.
- 3
Day 3: script the concession-and-ask
Write how you'll validate the surgeon's current outcomes, and write the exact evaluation-case ask — patient type, personal coverage, timeframe. The close is what candidates fumble; make it a reflex.
- 4
Day 2: drill the four objections with LAER
Rehearse Listen, Acknowledge, Explore, Respond for 'why change what works,' 'you'll slow my OR,' 'the last rep disappeared,' and 'your device is too new.' Say them out loud, timed to ten minutes.
- 5
Day 1: run a full timed rep and write your 30-60-90
Do the whole call against an AI surgeon or a peer, get scored, and cut where you ran long. Then draft the 30-60-90 so it's specific to credentialing, case coverage, and evaluations — not generic sales milestones.